Versifel CVR
Active substance
ATC code
Species
Cats from 9 weeks of age.
Indications
For active immunisation of cats to reduce mortality and clinical signs of disease caused by feline enteritis (panleucopaenia) virus, to reduce clinical signs of disease caused by feline rhinotracheitis virus and to prevent clinical signs of disease and reduce infection caused by feline calicivirus.
Onset of immunity occurs by approximately 3 weeks after the last dose of the Basic Vaccination Scheme.
The duration of immunity is at least 12 months.
Dose to be administered and administration route
Reconstitute the lyophilisate fraction aseptically with the complete contents of the solvent provided. Shake and immediately inject the contents of the vial subcutaneously 1 ml per dose.
Basic vaccination
In cats aged nine weeks and over, two injections of Versifel CVR, 3 to 4 weeks apart will stimulate full active immunity.
Re-vaccination
A single 1 ml dose is required on an annual basis.
For concurrent vaccination with Versifel FeLV, a single dose of Versifel CVR should be administered as described above. A single dose of Versifel FeLV should then be administered at a separate site via the subcutaneous route.
For simultaneous vaccination with Versifel FeLV, the contents of a single vial of Versifel CVR should be reconstituted with the contents of a single vial of Versifel FeLV in place of the diluent. Once mixed, the contents of the vial should appear as a slightly coloured (pink/orange) opaque suspension; the mixed vaccines should be injected immediately via the subcutaneous route.
Do not use chemically sterilised syringes or needles, as these might affect the effectiveness of the vaccine.
Adverse reactions
On rare occasions, transient increases in rectal temperature, transient lameness and transient lethargy may be observed as well as soft painless swellings (<1 cm average) may occur in the first 24 hours after vaccination, which may be evident as painless hard nodules for up to 21 days after dosing.
On very rare occasions, an anaphylactic reaction may occur which may require appropriate symptomatic treatment (e.g. adrenaline).
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
